09.12.2009 • Topics

Rosneft Considers Petchem Plant in Russia

Fareast Rosneft, Russia's largest oil producer, is considering plans to build a large petrochemical refinery on the country's Pacific coast that would be fed by crude from East Siberia, the company said. State-controlled Rosneft would seek approval for the project from its board within the next six to 12 months, should studies now under way prove the project to be viable, CFO Peter O'Brien said. "Market analysis and initial engineering and design work is being completed, upon review of which we will select the optimal configuration for the plant and better understand its likely cost," O'Brien said. Russia, the world's No. 2 oil exporter, is building the ESPO, or East Siberia-Pacific Ocean, pipeline to move oil from huge new fields in East Siberia to Asia, a move that will also diversify Moscow's reach beyond traditional European markets. Oil pipeline monopoly Transneft expects the first phase of the route to be complete by Dec. 25. The second stage, which will extend to the Pacific, is scheduled for completion by 2014. Rosneft did not confirm the size of the project or the investment that would be required.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.